PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
Reinhard ReussDepartment of Neurology, BKH Bayreuth, Bayreuth, GermanyAbstract: Current standard immunomodulatory therapy with interferons (IFNs) for relapsing–remitting multiple sclerosis (MS) exhibits proven, but limited, efficacy and increased side effects due to the need of frequent ap...
Guardado en:
Autor principal: | Reuss R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2f25c22240904349a17b83337b13b965 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Damiano Paolicelli, et al.
Publicado: (2009) -
Early stage and long term treatment of multiple sclerosis with interferon-β
por: Angela Applebee, et al.
Publicado: (2009) -
Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Reinhard Dummer, et al.
Publicado: (2009) -
Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Slobodan M Jankovic
Publicado: (2010) -
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop F, et al.
Publicado: (2013)